Dramatic decrease in CP diagnoses provides evidence of quality of neonatal care

Cerebral palsy is a neurodevelopmental condition that affects motor function, more often in children born prematurely. Because cerebral palsy is a result of brain injury received shortly before, during, or soon after birth, the number of infants being diagnosed with the condition is a good indicator of the quality of perinatal and neonatal care. An article soon to be published in the Journal of Pediatrics indicates that the rates of cerebral palsy have declined dramatically in the past 15 years.

Dr. Ingrid van Haastert and colleagues from the University Medical Center Utrecht in The Netherlands studied nearly 3000 infants born prematurely between 1990 and 2005. They found that 2.2% of the infants born between 2002 and 2005 were diagnosed with cerebral palsy, down from 6.5% for those born between 1990 and 1993. Such a dramatic decrease in the rate of cerebral palsy diagnoses provides evidence that care for infants right before, during, and shortly after birth has improved in the last 15 years.

The researchers also found that children who were diagnosed with cerebral palsy between 2002 and 2005 were less severely affected by the condition than those diagnosed earlier in the study. Among the infants studied, the most important risk factors for developing severe cerebral palsy were large hemorrhages and/or white matter lesions in the brain. "We found that a decrease in the occurrence of extensive cystic white matter lesions was the main reason for the fall in severe cerebral palsy," Dr. van Haastert explains.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New protein platform enhances cancer immunotherapy